It is with deep sadness that we inform you about the passing of Dr. Yoram Karmon, PhD- CEO & President.Dr. Yoram Karmon passed away unexpectedly by a septic shock on August, 2nd 2022. Dr. Yoram Karmon was 75 years old. He was the founder of PulseCath BV in 2007. The Board of Directors issued the following statement: “We are shocked and greatly saddened by the passing of Dr. Yoram Karmon. We will always remember his tireless efforts to make the company successful and continue the business according to his mission. We are forever grateful for his invaluable contribution.” We offer our sincere condolences to his family, who supported him every step of the way. Our hearts go out to Dr. Yoram Karmon family at this difficult time. Please keep them in your thoughts. Dr. Yoram Karmon, a creative entrepreneur with extensive experience in management at the senior level within premier biotechnology and medical […]
The firm is expanding its global distribution, generating innovation and new products to broaden the Company’s product portfolio to become the world’s circulatory support leader. Farmington, MI – June, 2022 – The CEO Views has identified PulseCath, a disruptor in the medical device market as one of the top 10 Healthcare Companies of the Year 2022. The firm’s unique and proprietary platform offers short-term circulatory support system to help cardiologists and cardiac surgeons address a wide range of patient’s issues. PulseCath has been instrumental in delivering early cardiac institutional support, non-invasive methods, and other great list of innovations in the medical device production and manufacturing arena thus reducing healthcare costs and improving patient outcomes. “It’s a great honor to announce PulseCath as one of the top 10 Healthcare Companies of the Year 2022,” said Ben Johnson, Managing Editor of The CEO Views. PulseCath is focused on developing ground-breaking technologies designed […]
We are pleased to announce our newest publication in the International Journal of Cardiology from the desk of Dr. Alexander Samol, Marcus Wiemer, Sven Kaese. Mechanical circulatory support devices are able to generate additional cardiac output or maintain sufficient circulation during high-risk PCI. They prospectively compared the hemodynamic and clinical performance of the new iVAC 2L® device with the Impella 2. 5® device during high-risk PCI. Please follow the link below for the results and the full publication.
Please follow the link below for the poster presentation by Dr. Marcelo Bastos: Effect of Pulsatile Mechanical Circulatory Support on Cardiac Mechanics (PULSE trial)
We are pleased to announce our newest publication in the Cardiovascular Revascularization Medicine from the desk of Prof. Nicolas van Mieghem and Dr. Marcelo Bastos. MCS is increasingly used in the context of high-risk percutaneous coronary intervention (PCI). The effect of the pulsatile iVAC 2L MCS on left ventricular loading conditions and myocardial oxygen consumption (MVO2) is unknown. In this publication, the Erasmus University Medical Centre & Kings College London showcase their clinical experiences with the iVAC 2L device and outline the impact on patients with advanced coronary artery disease at high to prohibitive operative risk in their practice. Please check this link for the full publication.
PulseCath is proud sponsor of the Transcatheter Interventions Online 2022. It is a free international event broadcast, led by course director, Prof. Nicolas van Mieghem from Erasmus MC, Rotterdam, the Netherlands. On day 2 (24 March at 3 pm CET) the section High Risk & Complex PCI will take place including Mechanical Circulatory Support. A live case will be performed by the EMC, Rotterdam, the Netherlands. For more information and registration.
United Kingdom, 2022 – GHP has announced the winners of the Technology Awards. GHP awarded PulseCath with the Technology Awards for Best Global Circulatory Support System Manufacturer 2021. We are really proud by receiving this award. Please check also the publication. In today’s digital age, technology plays a vital role in improving healthcare and helping health services. Interim Home Healthcare is one of the best health care centers as it helps in improving the quality of life by their effective treatments. Throughout the years, technology has evolved in the medical field from being able to provide 3D printing, to telehealth, robotic surgery and artificial organs, these advances have allowed the healthcare industry to excel in ways it could not before. GHP Awards Coordinator, Jazmin Collins has spoken about the success of the Awards programme: “Technology has evolved and has found a place in every single industry, healthcare being the most prominent […]
PulseCath is proud sponsor of the 6th ACTOS Amsterdam CTO symposium 2-3 December 2021. Looking forward to meet you there. For more information, please follow this link.
PulseCath is proud sponsor of the upcoming congress CSI FOCUS D-HF in Frankfurt at December 10-11, 2021. We would like to draw your attention to Friday 10th December to the presentation by Prof. Nicolas van Mieghem, Erasmus Medical Center, Rotterdam, The Netherlands: Insights from the PULSE Trial & iVAC 2L in MCS facilitated high-risk PCI. This is scheduled in the section Acute Mechanical Circulatory Support (15:40 – 17:10 CET). Want to learn more about iVAC 2L? Our experts are at your disposal at our booth.
PulseCath has been recognized as one of the “Top 10 MedTech Startups in Europe 2021” by MedTech Outlook Magazine. “We take pride in honoring PulseCath as one among the 10 MedTech startups that are specialized in providing innovative healthcare solutions for respective companies,” said Alex D’souza, Managing Editor of MedTech Outlook. We are very proud with this recognization and the award. Please check also the interview online via this link.